Press release
Fibromyalgia Treatment Landscape: FDA Approves TONMYA, First New Therapy in 15 Years | DelveInsight's Perspective on Market Impact, Competitive Landscape and Other Pipeline Therapies
Fibromyalgia Market Insight, Epidemiology and Market Forecast report
Key Fibromyalgia Market Highlights
*
TONMYA's approval is expected to be a key driver of the fibromyalgia treatment market growth, given its first-in-class status and differentiated therapeutic approach.
*
Fibromyalgia has a mean prevalence of 2.7% worldwide, with significant age and gender disparity.
*
Fibromyalgia Companies: Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), Sanofi S.A. (NASDAQ: SNY), AstraZeneca PLC (NASDAQ: AZN), Abbott Laboratories (NYSE: ABT), GlaxoSmithKline PLC (NYSE: GSK), Amgen Inc. (NASDAQ: AMGN), Viatris Inc. (NASDAQ: VTRS), and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Exagen Inc. (NASDAQ: XGN), Dogwood Therapeutics, Inc. (NASDAQ: DWTX), among others.
Market Impact and Fibromyalgia Patient Population
According to DelveInsight's Fibromyalgia Market Insight, Epidemiology and Market Forecast report [https://www.delveinsight.com/report-store/fibromyalgia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr], fibromyalgia represents a significant global health burden with a mean prevalence of 2.7% worldwide, showing regional variations with higher rates in America compared to Europe. In the United States, the condition affects approximately 2% of the general population, with a pronounced gender disparity where women are disproportionately affected, representing approximately 80% of total diagnosed cases.
The condition is characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction, significantly impacting patients' quality of life. It is the leading cause of generalized musculoskeletal pain in women and represents a significant economic burden, with annual costs estimated at over $9 billion in the United States alone.
Furthermore, the report highlights that the fibromyalgia treatment market is projected to grow at a significant CAGR. TONMYA's approval is expected to be a key driver of this growth trajectory, given its first-in-class status and differentiated therapeutic approach.
Download the Fibromyalgia Market report to understand which other factors are driving the therapeutic market @ Fibromyalgia Market Trends [https://www.delveinsight.com/sample-request/fibromyalgia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
TONMYA Treatment Approach
TONMYA represents a first-in-class, non-opioid analgesic designed for once-daily bedtime administration. The sublingual formulation allows for rapid absorption into the bloodstream while avoiding first-pass hepatic metabolism, potentially reducing the formation of long-lasting metabolites associated with traditional oral cyclobenzaprine formulations.
"The TONMYA approval addresses a critical unmet medical need in fibromyalgia treatment," said Seth Lederman, M.D., CEO of Tonix Pharmaceuticals. "At Tonix, we recognized the transformative potential of pursuing a new approach with TONMYA for fibromyalgia, a chronic overlapping pain condition that has gone without innovation for many years."
TONMYA Clinical Validation and Efficacy
The TONMYA FDA approval was based on robust clinical evidence from two pivotal Phase 3 trials (RELIEF and RESILIENT) involving nearly 1,000 fibromyalgia patients. Key clinical outcomes include a statistically significant reduction in daily pain scores versus placebo at 14 weeks (primary endpoint), with a greater percentage of patients experiencing clinically meaningful ( greater than or equal to 30%) pain improvement after 3 months.
Fibromyalgia Competitive Landscape and Market Positioning
TONMYA, which is expected to be commercially available in the fourth quarter of 2025, enters a highly competitive fibromyalgia treatment landscape that has been dominated by three FDA-approved therapies for over 15 years: LYRICA (pregabalin) by Pfizer Inc., which historically commands the largest market share; CYMBALTA (duloxetine) by Eli Lilly and Company; and SAVELLA (milnacipran), now available through multiple generic manufacturers.
The broader competitive ecosystem includes established pharmaceutical giants such as Johnson & Johnson, AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Amgen Inc., Viatris Inc., and Teva Pharmaceutical Industries Ltd., which compete through off-label prescribing of pain management and antidepressant medications.
Explore the Fibromyalgia Drug Battle: TONMYA vs. LYRICA vs. CYMBALTA vs. SAVELLA. Discover how these breakthrough Fibromyalgia therapies compare in efficacy, safety, cost, and market impact @ Fibromyalgia Drugs Market [https://www.delveinsight.com/sample-request/fibromyalgia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Emerging Fibromyalgia Pipeline Therapies
Several companies are actively developing next-generation fibromyalgia therapies, including Aptinyx Inc. with NMDA receptor modulator programs, Prismic Pharmaceuticals Inc. focusing on novel pain pathways, Scilex Holding advancing non-opioid analgesics, Tryptamine Therapeutics exploring psychedelic-assisted therapies, and Intec Pharma Ltd. developing gastroretentive drug delivery systems.
Furthermore, regional players such as Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited compete primarily in the generic space. Despite this crowded landscape, TONMYA's first-in-class status and unique sublingual delivery mechanism provide significant competitive differentiation, positioning Tonix Pharmaceuticals to capture substantial market share in a therapeutic area that has remained largely unchanged for over a decade.
Discover more fibromyalgia pipeline therapies and the clinical development progress they are making @ Fibromyalgia Clinical Pipeline [https://www.delveinsight.com/sample-request/fibromyalgia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Broader TONMYA Therapeutic Pipeline
Beyond fibromyalgia, Tonix Pharmaceuticals is investigating TNX-102 SL (now TONMYA) for additional indications, including acute stress reaction, posttraumatic stress disorder, and Long COVID-associated multi-site pain, potentially expanding its market opportunity significantly.
Industry Expert Perspective
Dr. Andrea Chadwick, M.D., MSc, FASA, at the University of Kansas Health System, commented on the novel administration approach: "Treatments that are processed through the liver can result in metabolites that could affect a medicine's efficacy and safety over time. TONMYA is administered sublingually, which is designed to reduce pain quickly and durably with a tolerable safety profile."
Learn more about what other Industry experts are saying about TONMYA FDA Approval and how it will impact the fibromyalgia treatment market @ Key Opinion Leaders on Fibromyalgia Market [https://www.delveinsight.com/sample-request/fibromyalgia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Looking Forward
The TONMYA approval represents a paradigm shift in fibromyalgia treatment and demonstrates the potential for innovative drug delivery approaches to address complex chronic pain conditions. Delveinsight's analysts underline that as the pharmaceutical industry continues to focus on patient-centric therapeutic solutions, TONMYA's success may pave the way for similar innovations in other underserved therapeutic areas.
Table of Contents
1. Key Insights
2. Executive Summary of Fibromyalgia
3. Competitive Intelligence Analysis for Fibromyalgia
4. Fibromyalgia Market Overview at a Glance
5. Fibromyalgia: Disease Background and Overview
6. Fibromyalgia Patient Journey
7. Fibromyalgia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Fibromyalgia Unmet Needs
10. Key Endpoints of Fibromyalgia Treatment
11. Fibromyalgia Marketed Products
12. Fibromyalgia Emerging Therapies
13. Fibromyalgia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Fibromyalgia
17. KOL Views
18. Fibromyalgia Market Drivers
19. Fibromyalgia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight Business Research
DelveInsight is a leading business consultant and market research firm in the pharmaceutical and healthcare sectors. The company provides comprehensive market intelligence, competitive analysis, and strategic consulting services to pharmaceutical companies, biotechnology firms, and healthcare organizations worldwide.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Annad
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fibromyalgia-treatment-landscape-fda-approves-tonmya-first-new-therapy-in-15-years-delveinsights-perspective-on-market-impact-competitive-landscape-and-other-pipeline-therapies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fibromyalgia Treatment Landscape: FDA Approves TONMYA, First New Therapy in 15 Years | DelveInsight's Perspective on Market Impact, Competitive Landscape and Other Pipeline Therapies here
News-ID: 4155062 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Fibromyalgia
Government Initiatives On Musculoskeletal Health Propel Growth In The Fibromyalg …
The Fibromyalgia Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Fibromyalgia Treatment Market?
The market for the treatment of fibromyalgia has been expanding consistently in past years. At a compound annual growth rate (CAGR) of 3.9%, it is…
SN Clinic's Effective Treatment of Fibromyalgia Symptoms
Image: https://www.globalnewslines.com/uploads/2025/02/1740408683.jpg
SN Clinic Logo
Fibromyalgia can be a debilitating condition, but SN Clinic offers hope through innovative treatments like MLS Laser Therapy and complementary massage therapies. By addressing chronic pain through a holistic approach, patients can experience significant relief and an improved quality of life.
What is Fibromyalgia and What Does Current Data Say?
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Affecting…
Prominent Fibromyalgia Treatment Market Trend for 2025: Market Leaders Focus On …
What Are the Projected Growth and Market Size Trends for the Fibromyalgia Treatment Market?
The Fibromyalgia Treatment market is expected to grow from $2.79 billion in 2024 to $2.9 billion in 2025, at a CAGR of 3.9%. This growth is attributed to the increasing prevalence of fibromyalgia, greater awareness about the condition, government initiatives, and rising disposable incomes.
The fibromyalgia treatment market is projected to see steady growth, reaching $3.45 billion by…
Advancements in Fibromyalgia Treatments Driving Market Expansion
The fibromyalgia treatment market is experiencing a steady upward trajectory, with significant growth expected over the next decade. Estimated at USD 2.77 billion in 2023, the market is projected to reach approximately USD 4.13 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032. This expansion is driven by several key factors, including advances in treatment options, increasing demand for effective therapies, and…
Fibromyalgia - Drug Pipeline Landscape, 2022
Fibromyalgia is a is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues.
Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD.
To know more about Fibromyalgia - Drug Pipeline, visit - https://www.globalinsightservices.com/reports/fibromyalgia-drug-pipeline-landscape-2022/
Fibromyalgia…
Fibromyalgia Treatment Market 2022 | Increased Morbidity of Fibromyalgia Along w …
According to Precision Business Insights (PBI), the latest report, the Fibromyalgia Treatment market is expected to be valued at USD 3,017.9 million in 2022, growing at an 3.8% CAGR from 2022 to 2028. Fibromyalgia treatment market analysis projects that the increased prevalence of fibromyalgia and its related complication compelled the introduction of targeted & precise treatment methods for fibromyalgia. Also, the increase in awareness about fibromyalgia will give the required…
